Burning Rock Biotech Ltd. (BNR)
|Net Income (ttm)||-66.04M|
|Trading Day||January 15|
|Day's Range||27.35 - 34.35|
|52-Week Range||19.07 - 34.35|
Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.
OncoCyte's stock soars after licensing deal with China-based company, days after insiders acquired shares
Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing...
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 13 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen Plus that targets therapy ... [Read more...]
Diagnostics & Research
|IPO Date |
Jun 12, 2020
|Stock Exchange |
|Ticker Symbol |
According to 3 analysts, the average rating for BNR stock is "Strong Buy." The 12-month stock price forecast is 31.92, which is a decrease of -6.94% from the latest price.